Jeffrey M Isner

US Patent:

RE37933, Dec 10, 2002

Filed:

Dec 21, 2000

Appl. No.:

09/740876

Inventors:

Didier Branellec - Brie-Comte-Robert, FR
Kenneth Walsh - Carlisle MA
Jeffrey M. Isner - Weston MA
Patrice Denefle - Saint Maur, FR

Assignee:

Case Western Reserve University - Cleveland OH

International Classification:

A61K 3576

US Classification:

424 932, 435456, 4353201, 435325, 435375, 514 44, 536 235

Abstract:

The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.

US Patent:

6569428, May 27, 2003

Filed:

Jan 11, 1999

Appl. No.:

09/228020

Inventors:

Jeffrey M. Isner - Weston MA
Takayuki Asahara - Arlington MA

Assignee:

St. Elizabeths Medical Center of Boston, Inc. - Boston MA

International Classification:

A61K 3512

US Classification:

424 937, 514 44, 536 231, 536 235, 536 236, 536 237, 435325

Abstract:

Pharmaceutical products are provided comprising EC progenitors for use in methods for regulating angiogenesis, i. e. , for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting an angiogenesis modulator to specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e. g. , anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

US Patent:

6676937, Jan 13, 2004

Filed:

Mar 9, 1999

Appl. No.:

09/265041

Inventors:

Jeffrey M. Isner - Weston MA
Takayuki Asahara - Arlington MA

Assignee:

Caritas St. Elizabeths Medical Center of Boston Inc. - Boston MA

International Classification:

A01N 6300

US Classification:

424 937, 424 851, 514 44, 435325, 435355, 435372, 435455

Abstract:

The present invention generally provides methods for modulating formation of new blood vessels. In one embodiment, the methods include administering to a mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF) sufficient to form the new blood vessels. Additionally provided are methods for preventing or reducing the severity of blood vessel damage in a mammal which methods preferably include administering to the mammal an effective amount of GM-CSF. Provided also as part of this invention are pharmaceutical products and kits for inducing formation of new blood vessels in the mammal.

US Patent:

7125856, Oct 24, 2006

Filed:

Apr 11, 2000

Appl. No.:

09/546733

Inventors:

Jeffrey M. Isner - Weston MA, US

Assignee:

St. Elizabeth's Medical Center of Boston, Inc. - Boston MA

International Classification:

A01N 43/04
A61K 31/70

US Classification:

514 44

Abstract:

A method for treating peripheral neuropathy, particularly ischemic peripheral neuropathy, is provided. The method involves administering to subjects in need of such treatment an effective amount of an angiogenic growth factor to alleviate a symptom of the neuropathy.

US Patent:

8075880, Dec 13, 2011

Filed:

Mar 17, 2003

Appl. No.:

10/390559

Inventors:

Jeffrey M. Isner - Weston MA, US
Linda Isner, legal representative - Weston MA, US
Takayuki Asahara - Arlington MA, US
Douglas W. Losordo - Winchester MA, US

Assignee:

Steward St. Elizabeth's Medical Center of Boston, Inc. - Brighton MA

International Classification:

C12N 5/0789
A01N 63/02

US Classification:

424 937, 435372

Abstract:

In accordance with the present invention, EC progenitors can be used in a method for regulating angiogenesis, i. e. , enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e. g. anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.

US Patent:

20020151489, Oct 17, 2002

Filed:

Oct 2, 2001

Appl. No.:

09/970088

Inventors:

Edwin Gravereaux - Brookline MA, US
Marcy Silver - Bolton MA, US
Young-Sup Yoon - Watertown MA, US
Jeffrey Isner - Weston MA, US
Linda Isner - Weston MA, US

Assignee:

St. Elizabeth's Medical Center of Boston, Inc.

International Classification:

A61K038/18

US Classification:

514/012000

Abstract:

The present invention provides methods for promoting the growth of new lymph vessels (lymphangiogenesis). Generally, such methods include administering at least one vascular endothelian factor (VEGF) such as VEGF-2. In one embodiment, therapeutic methods for treating lymphedema and related disorders in a human patient are disclosed. The VEGF can be provided by any suitable means including direct injection of a nucleic acid encoding same or an active fragment thereof. Also provided are pharmaceutical products for promoting lymphangiogenesis as well as a test system for screening compounds capable of inducing new lymph vessel growth.

US Patent:

20020155421, Oct 24, 2002

Filed:

Sep 21, 2001

Appl. No.:

09/961128

Inventors:

Marianne Kearney - Watertown MA, US
Jeffrey Isner - Weston MA, US
Linda Isner - Weston MA, US

International Classification:

C12Q001/00
C12Q001/68

US Classification:

435/004000, 435/006000

Abstract:

The present invention provides novel methods for determining the bioactivity of a plasmid encoding for an endothelial cell mitogen. The invention also provides a method to optimize a plasmid construct for use in a gene therapy procedure. Further, the invention provides a quantitative quality control assay for evaluating a batch of plasmid DNA prior to use in a gene therapy treatment.

US Patent:

20040228834, Nov 18, 2004

Filed:

Oct 28, 2003

Appl. No.:

10/696391

Inventors:

Jeffrey Isner - Weston MA, US
Takayuki Asahara - Kanagawa, JP
Douglas Losordo - Winchester MA, US
Linda Isner - Weston MA, US

International Classification:

A61K038/19

US Classification:

424/085100

Abstract:

The present invention generally provides compositions and methods for modulating formation of new blood vessels. The invention has a wide spectrum of applications including use to prevent or treat cardiovascular disease.